PIKfyve抑制在多发性骨髓瘤中破坏自噬和溶酶体功能,增加MHC表达和胆固醇代谢
研究开发了PIKfyve抑制剂PIK001及其类似物,在体外对多发性骨髓瘤(MM)有强效抗肿瘤活性,与venetoclax和selinexor协同,且在来那度胺耐药模型中保持疗效。多组学分析发现PIKFYVE N1939K突变和自噬能力异质性。PIK001暴露显著增加胆固醇代谢和MHC I类表达。PIKfyve抑制在急性髓系白血病、黑色素瘤和肾癌中也显示选择性细胞毒性。
要点
- PIK001是强效选择性PIKfyve抑制剂,体外对MM有抗肿瘤活性,与venetoclax和selinexor协同。
- PIK001在来那度胺耐药模型中保持疗效。
- PIK001暴露显著增加胆固醇代谢和MHC I类表达,可能影响肿瘤免疫。
核心结论
- PIKfyve抑制是MM和其他血液恶性肿瘤的有效靶点,揭示了敏感性和耐药机制,为临床前和临床开发奠定基础。
研究设计与样本
- 研究开发并表征了PIK001及其类似物,为强效选择性PIKfyve小分子抑制剂;进行体外抗MM活性评估及多组学表征。
主要发现
- PIK001在体外显示强效抗MM活性,与venetoclax和selinexor协同,在来那度胺耐药模型中保持疗效。
- 对敏感和耐药同源细胞系的多组学表征发现PIKFYVE N1939K催化域突变和自噬能力异质性改变。
- PIK001暴露导致胆固醇代谢显著增加和MHC I类表达上调。
- PIKfyve抑制在急性髓系白血病、黑色素瘤和肾癌中显示选择性细胞毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously reported a chemogenomics screen that unexpectedly identified phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as a vulnerable target in multiple myeloma (MM). PIKfyve is an essential regulator of lysosomal function and autophagy. Given the high basal requirement for autophagy in MM for sustainable immunoglobulin synthesis, targeting autophagy holds clinical potential as a novel therapeutic avenue. Here, we report the development and characterization of PIK001 and analogs, potent and selective novel small-molecule inhibitors of PIKfyve. PIK001 demonstrated potent anti-MM activity in vitro, as well as synergistic activity with established anti-MM agents (including venetoclax and selinexor), while retaining efficacy in lenalidomide-resistant models. Multiomic characterization of isogenic cell lines sensitive and resistant to PIK001 identified a catalytic domain mutation (PIKFYVE N1939K) and heterogenous alterations in autophagy capabilities. Importantly, we noted that PIK001 exposure also resulted in significantly increased cholesterol metabolism and upregulation of major histocompatibility complex (MHC) class I expression, with potential implications in tumor immunity. Beyond MM, PIKfyve inhibition also shows selective cytotoxicity in acute myeloid leukemia, melanoma, and renal cancer, highlighting broader therapeutic potential. These findings establish PIKfyve inhibition as a valid target for MM and other hematologic malignancies, provide insights into mechanisms of sensitivity and resistance, and lay the foundation for further preclinical (particularly the role of cholesterol metabolism and tumor immunity) and clinical development.
引用
- Bonolo de Campos C, He R, Pelino T, et al. PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism. Blood. 2026. PMID: 41191517. doi:10.1182/blood.2025030061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。